Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(50%)
Results Posted
100%(1 trials)

Phase Distribution

Ph phase_2
2
50%
Ph phase_1
1
25%
Ph phase_3
1
25%

Phase Distribution

1

Early Stage

2

Mid Stage

1

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
2(50.0%)
Phase 3Large-scale testing
1(25.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(2)
Completed(1)
Terminated(1)

Detailed Status

Withdrawn1
Active, not recruiting1
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 11 (25.0%)
Phase 22 (50.0%)
Phase 31 (25.0%)

Trials by Status

withdrawn125%
active_not_recruiting125%
completed125%
recruiting125%

Recent Activity

2 active trials
Showing 4 of 4
active_not_recruitingphase_2

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

NCT05996471
recruitingphase_3

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

NCT07682961
completedphase_1

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

NCT03149848
withdrawnphase_2

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa

NCT02462772

Clinical Trials (4)

Showing 4 of 4 trials
NCT05996471Phase 2

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Active Not Recruiting
NCT07682961Phase 3

Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy

Recruiting
NCT03149848Phase 1

Effect of Rifabutin on the Pharmacokinetics of Oral Cabotegravir in Healthy Subjects

Completed
NCT02462772Phase 2

Safety and Acceptability of Cabotegravir in HIV Uninfected Women in KwaZulu-Natal, South Africa

Withdrawn

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4